Showing results (211-220 of 318) with videos related to
Sort By:
Pageof 32
Journal of the National Cancer Institute|September 7, 2023
Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancerMaria Vittoria Dieci, PierFranco Conte, Giancarlo Bisagni, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2006
Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patientsAlberto Bottini, Daniele Generali, Maria Pia Brizzi, et al.Cancer Letters|April 10, 2012
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clonesAndrea Cavazzoni, Mara A Bonelli, Claudia Fumarola, et al.Oncotarget|November 8, 2017
Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancerManuela Milani, Sergio Venturini, Simone Bonardi, et al.Cancers|November 13, 2020
Early Changes of the Standardized Uptake Values (SUVmax) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast CancerMarianna Sirico, Ottavia Bernocchi, Navid Sobhani, et al.Heliyon|November 18, 2024
Assessing the long-term prognostic ability of the 70 gene expression signature MammaPrint in an Italian single-center prospective cohort study of early-stage intermediate-risk breast cancer patientsDaniele Generali, Andrea Rocca, Carla Strina, et al.BMC Cancer|May 21, 2017
The PREgnancy and FERtility (PREFER) study: an Italian multicenter prospective cohort study on fertility preservation and pregnancy issues in young breast cancer patientsMatteo Lambertini, Paola Anserini, Valeria Fontana, et al.Future Oncology (London, England)|November 29, 2017
Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?Alessandra Fabi, Diana Giannarelli, Luca Moscetti, et al.Medical Sciences (Basel, Switzerland)|November 24, 2025
Virtual Biomarkers and Simplified Metrics in the Modeling of Breast Cancer Neoadjuvant Therapy: A Proof-of-Concept Case Study Based on Diagnostic ImagingGraziella Marino, Maria Valeria De Bonis, Marisabel Mecca, et al.JAMA|January 1, 2016
Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical TrialMatteo Lambertini, Luca Boni, Andrea Michelotti, et al.Pageof 32